Fair Pricing of Pharmaceuticals: Insights into China's NRDL Negotiation
Although NRDL negotiation involves multiple aspects, at its core, the most fundamental issue is the fair pricing of innovative pharmaceuticals.
NHSA Proposes Launch Price Framework and Aligns Pricing Policies with Drug Lifecycle
At a recent industry investor conference, Weng Linjia, Deputy Director of the Pharmaceutical Pricing and Tender Procurement Department, National Healthcare
Wonder Sir Founder on the State of Rare Disease Patient Organizations in China
This is the last part of my conversation with Wonder Sir founder Chen Yiwei. You can find our interview'
NHSA Insurance Funding Expert Zheng Jie: Shifting from Excessive Price Reduction to Value-Based Procurement for China's Drug Pricing Dilemma
At the 5th China Rare Disease Cooperation and Exchange Conference, Zheng Jie, the leader of the Insurance Funding Analysis Expert
Wonder Sir Founder on Pharma Success: The Importance of Early Investment and Trust in China
“In my capacity as a researcher, I've had experience in both scientific research and drug development. Additionally, as
Wonder Sir Founder Chen Yiwei on China’s Rare Disease Definition and Recent Policy Boost for Foreign CGT Investment
Motivated by a profound sense of purpose and deeply moved by the suffering of Chinese rare disease patients, Chen Yiwei,
Improving Access to Innovative Drugs: Can China’s Dual-Channel Policy Deliver?
To tackle the hospital formulary access issues faced by some NRDL-negotiated drugs, the National Healthcare Security Administration (NHSA) introduced the
